-
1
-
-
0030957724
-
Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions
-
Goodman WK, Ward H, Kablinger A, et al. Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions. J Clin Psychiatry. 1997;58 Suppl 5:32-49. (Pubitemid 27255355)
-
(1997)
Journal of Clinical Psychiatry
, vol.58
, Issue.SUPPL. 5
, pp. 32-49
-
-
Goodman, W.K.1
Ward, H.2
Kablinger, A.3
Murphy, T.4
-
2
-
-
0029160813
-
Overview of the pharmacokinetics of fluvoxamine
-
van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet. 1995;29 Suppl 1:1-9.
-
(1995)
Clin Pharmacokinet
, vol.29
, Issue.SUPPL. 1
, pp. 1-9
-
-
Van Harten, J.1
-
3
-
-
29244465500
-
Fluvoxamine: A selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder
-
DOI 10.1517/14656566.6.15.2727
-
Dell'Osso B, Allen A, Hollander E. Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder. Expert Opin Pharmacother. 2005;6:2727-2740. (Pubitemid 41824387)
-
(2005)
Expert Opinion on Pharmacotherapy
, vol.6
, Issue.15
, pp. 2727-2740
-
-
Dell'Osso, B.1
Allen, A.2
Hollander, E.3
-
4
-
-
85047681662
-
The use of escitalopram beyond major depression: Pharmacological aspects, efficacy and tolerability in anxiety disorders
-
DOI 10.1517/17425225.3.5.741
-
Bareggi SR, Mundo E, Dell'Osso B, et al. The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007;3:741-753. (Pubitemid 351320641)
-
(2007)
Expert Opinion on Drug Metabolism and Toxicology
, vol.3
, Issue.5
, pp. 741-753
-
-
Bareggi, S.R.1
Mundo, E.2
Dell'Osso, B.3
Altamura, A.C.4
-
5
-
-
34047200959
-
An update on the pharmacological treatment of obsessive-compulsive disorder
-
DOI 10.1517/14656566.8.5.563
-
Fontenelle LF, Nascimento AL, Mendlowicz MV, et al. An update on the pharmacological treatment of obsessive-compulsive disorder. Expert Opin Pharmacother. 2007;8(5):563-583. (Pubitemid 46547011)
-
(2007)
Expert Opinion on Pharmacotherapy
, vol.8
, Issue.5
, pp. 563-583
-
-
Fontenelle, L.F.1
Nascimento, A.L.2
Mendlowicz, M.V.3
Shavitt, R.G.4
Versiani, M.5
-
6
-
-
0026072115
-
A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder
-
Leonard HL, Swedo SE, Lenane MC, et al. A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry. 1991;48:922-927.
-
(1991)
Arch Gen Psychiatry
, vol.48
, pp. 922-927
-
-
Leonard, H.L.1
Swedo, S.E.2
Lenane, M.C.3
-
7
-
-
0030799748
-
Addition of desipramine to serotonin reuptake inhibitors in treatment- Resistant obsessive-compulsive disorder
-
Barr LC, Goodman WK, Anand A, et al. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Am J Psychiatry. 1997;154:1293-1295. (Pubitemid 27369184)
-
(1997)
American Journal of Psychiatry
, vol.154
, Issue.9
, pp. 1293-1295
-
-
Barr, L.C.1
Goodman, W.K.2
Anand, A.3
McDougle, C.J.4
Price, L.H.5
-
8
-
-
0025294010
-
Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine
-
Goodman WK, Price LH, Delgado PL, et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry. 1990;47:577-585.
-
(1990)
Arch Gen Psychiatry
, vol.47
, pp. 577-585
-
-
Goodman, W.K.1
Price, L.H.2
Delgado, P.L.3
-
9
-
-
0021815938
-
Tricyclic antidepressants in obsessive-compulsive disorder: Antiobsessional or antidepressant agents? II
-
Mavissakalian M, Turner SM, Michelson L, et al. Tricyclic antidepressants in obsessive-compulsive disorder: antiobsessionals or antidepressant agents? II. Am J Psychiatry. 1985;142:572-576. (Pubitemid 15034625)
-
(1985)
American Journal of Psychiatry
, vol.142
, Issue.5
, pp. 572-576
-
-
Mavissakalian, M.1
Turner, S.M.2
Michelson, L.3
Jacob, R.4
-
10
-
-
0036109031
-
Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder
-
DOI 10.1097/00004714-200206000-00012
-
Ackerman DL, Greenland S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol. 2002;22:309-317. (Pubitemid 34546847)
-
(2002)
Journal of Clinical Psychopharmacology
, vol.22
, Issue.3
, pp. 309-317
-
-
Ackerman, D.L.1
Greenland, S.2
-
11
-
-
0028916905
-
Efficacy of drug treatment in obsessive-compulsive disorder. a meta-analytic review
-
Piccinelli M, Pini S, Bellantuono C, et al. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br J Psychiatry. 1995;166:424-443.
-
(1995)
Br J Psychiatry
, vol.166
, pp. 424-443
-
-
Piccinelli, M.1
Pini, S.2
Bellantuono, C.3
-
12
-
-
33744907721
-
Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder
-
DOI 10.1016/j.pnpbp.2005.11.005, PII S0278584605003490
-
El Mansari M, Blier P. Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:362-373. (Pubitemid 43841738)
-
(2006)
Progress in Neuro-Psychopharmacology and Biological Psychiatry
, vol.30
, Issue.3
, pp. 362-373
-
-
El Mansari, M.1
Blier, P.2
-
13
-
-
0033778681
-
Effects of Fluvoxamine treatment on the in vivo binding of [F-18]FESP in drug naive depressed patients: A pet study
-
DOI 10.1006/nimg.2000.0619
-
Moresco RM, Colombo C, Fazio F, et al. Effects of fluvoxamine treatment on the in vivo binding of [F-18]FESP in drug naive depressed patients: a PET study. Neuroimage. 2000;12:452-465. (Pubitemid 30765722)
-
(2000)
NeuroImage
, vol.12
, Issue.4
, pp. 452-465
-
-
Moresco, R.M.1
Colombo, C.2
Fazio, F.3
Bonfanti, A.4
Lucignani, G.5
Messa, C.6
Gobbo, C.7
Galli, L.8
Del Sole, A.9
Lucca, A.10
Smeraldi, E.11
-
14
-
-
0037383195
-
High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography
-
DOI 10.1001/archpsyc.60.4.386
-
Suhara T, Takano A, Sudo Y, et al. High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry. 2003;60:386-391. (Pubitemid 36402999)
-
(2003)
Archives of General Psychiatry
, vol.60
, Issue.4
, pp. 386-391
-
-
Suhara, T.1
Takano, A.2
Sudo, Y.3
Ichimiya, T.4
Inoue, M.5
Yasuno, F.6
Ikoma, Y.7
Okubo, Y.8
-
15
-
-
33646684492
-
Time course of in vivo 5-HTT transporter occupancy by fluvoxamine
-
DOI 10.1097/01.jcp.0000203201.34323.d3, PII 0000471420060400000014
-
Takano A, Suhara T, Ichimiya T. Time course of in vivo 5-HTT transporter occupancy by fluvoxamine. J Clin Psychopharmacol. Apr; 2006;26(2):188-191. (Pubitemid 43740345)
-
(2006)
Journal of Clinical Psychopharmacology
, vol.26
, Issue.2
, pp. 188-191
-
-
Takano, A.1
Suhara, T.2
Ichimiya, T.3
Yasuno, F.4
Suzuki, K.5
-
16
-
-
24944548298
-
Effects of dopaminergic and serotonergic manipulation on emotional processing: A pharmacological fMRI study
-
DOI 10.1016/j.neuroimage.2005.05.039, PII S1053811905003599
-
Takahashi H, Yahata N, Koeda M. Effects of dopaminergic and serotonergic manipulation on emotional processing: a pharmacological fMRI study. Neuroimage. 2005;27:991-1001. (Pubitemid 41317266)
-
(2005)
NeuroImage
, vol.27
, Issue.4
, pp. 991-1001
-
-
Takahashi, H.1
Yahata, N.2
Koeda, M.3
Takano, A.4
Asai, K.5
Suhara, T.6
Okubo, Y.7
-
17
-
-
16544392764
-
The role of dopamine in obsessive-compulsive disorder: Preclinical and clinical evidence
-
Denys D, Zohar J, Westenberg HG. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry. 2004;65 Suppl 14:11-17.
-
(2004)
J Clin Psychiatry
, vol.65
, Issue.SUPPL. 14
, pp. 11-17
-
-
Denys, D.1
Zohar, J.2
Westenberg, H.G.3
-
18
-
-
33845686605
-
2 receptors: A pet study on OCD drug-naïve patients
-
DOI 10.1038/sj.npp.1301199, PII 1301199
-
Moresco RM, Pietra L, Henin M, et al. Fluvoxamine treatment and D2 receptors: a pet study on OCD drug-naïve patients. Neuropsychopharmacology. 2007;32:197-205. (Pubitemid 44967798)
-
(2007)
Neuropsychopharmacology
, vol.32
, Issue.1
, pp. 197-205
-
-
Moresco, R.M.1
Pietra, L.2
Henin, M.3
Panzacchi, A.4
Locatelli, M.5
Bonaldi, L.6
Carpinelli, A.7
Gobbo, C.8
Bellodi, L.9
Perani, D.10
Fazio, F.11
-
19
-
-
34948866293
-
Dopamine transporter density in the basal ganglia in obsessive-compulsive disorder, measured with [123I]IPT SPECT before and after treatment with serotonin reuptake inhibitors
-
Kim CH, Cheon KA, Koo MS, et al. Dopamine transporter density in the basal ganglia in obsessive-compulsive disorder, measured with [123I]IPT SPECT before and after treatment with serotonin reuptake inhibitors. Neuropsychobiology. 2007;55:156-162
-
(2007)
Neuropsychobiology
, vol.55
, pp. 156-162
-
-
Kim, C.H.1
Cheon, K.A.2
Koo, M.S.3
-
20
-
-
33749852123
-
Sigma receptor ligands: Possible application as therapeutic drugs and as radiopharmaceuticals
-
DOI 10.2174/138161206778559614
-
Hashimoto K, Ishiwata K. Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Curr Pharm Des. 2006;12: 3857-3876. (Pubitemid 44560699)
-
(2006)
Current Pharmaceutical Design
, vol.12
, Issue.30
, pp. 3857-3876
-
-
Hashimoto, K.1
Ishiwata, K.2
-
21
-
-
57349115973
-
The sigma enigma: Can sigma receptors provide a novel target for disorders of mood and cognition
-
Stahl SM. The sigma enigma: can sigma receptors provide a novel target for disorders of mood and cognition. J Clin Psychiatry, 2008;69:1673-1674.
-
(2008)
J Clin Psychiatry
, vol.69
, pp. 1673-1674
-
-
Stahl, S.M.1
-
22
-
-
0030594575
-
Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain
-
DOI 10.1016/0014-2999(96)00254-3
-
Narita N, Hashimoto K, Tomitaka S, et al. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol. 1996;307:117-119. (Pubitemid 26226293)
-
(1996)
European Journal of Pharmacology
, vol.307
, Issue.1
, pp. 117-119
-
-
Narita, N.1
Hashimoto, K.2
Tomitaka, S.-I.3
Minabe, Y.4
-
23
-
-
34748820517
-
11C]SA4503
-
DOI 10.1016/j.biopsych.2007.04.001, PII S0006322307003216, Bipolar Disorder and OCD: Circuitry of Impulsive and Compulsive Behaviors
-
Ishikawa M, Ishiwata K, Ishii K, et al. High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503. Biol Psychiatry. 2007;62:878-883. (Pubitemid 47488223)
-
(2007)
Biological Psychiatry
, vol.62
, Issue.8
, pp. 878-883
-
-
Ishikawa, M.1
Ishiwata, K.2
Ishii, K.3
Kimura, Y.4
Sakata, M.5
Naganawa, M.6
Oda, K.7
Miyatake, R.8
Fujisaki, M.9
Shimizu, E.10
Shirayama, Y.11
Iyo, M.12
Hashimoto, K.13
-
24
-
-
34247134612
-
1 receptor in inhibiting activity of fluvoxamine on marble-burying behavior: Comparison with paroxetine
-
DOI 10.1016/j.ejphar.2007.02.019, PII S0014299907002063
-
Egashira N, Harada S, Okuno R, et al. Involvement of the sigma1 receptor in inhibiting activity of fluvoxamine on marble-burying behavior: comparison with paroxetine. Eur J Pharmacol. 2007;563:149-154. (Pubitemid 46602243)
-
(2007)
European Journal of Pharmacology
, vol.563
, Issue.1-3
, pp. 149-154
-
-
Egashira, N.1
Harada, S.2
Okuno, R.3
Matsushita, M.4
Nishimura, R.5
Mishima, K.6
Iwasaki, K.7
Orito, K.8
Fujiwara, M.9
-
25
-
-
33748092384
-
Animal Models of Obsessive-Compulsive Disorder: Rationale to Understanding Psychobiology and Pharmacology
-
DOI 10.1016/j.psc.2006.02.007, PII S0193953X06000207
-
Korff S, Harvey BH. Animal models of obsessive-compulsive disorder: rationale to understanding psychobiology and pharmacology. Psychiatr Clin North Am. 2006;29: 371-390. (Pubitemid 44294451)
-
(2006)
Psychiatric Clinics of North America
, vol.29
, Issue.2
, pp. 371-390
-
-
Korff, S.1
Harvey, B.H.2
-
26
-
-
0030906968
-
Clinical pharmacokinetics of fluvoxamine: Applications to dosage regimen design
-
DeVane CL, Gill HS. Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design. J Clin Psychiatry. 1997;58 Suppl 5:7-14.
-
(1997)
J Clin Psychiatry
, vol.58
, Issue.SUPPL. 5
, pp. 7-14
-
-
DeVane, C.L.1
Gill, H.S.2
-
29
-
-
0030610929
-
19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder
-
Strauss WL, Layton ME, Hayes CE, et al. 19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder. Am J Psychiatry. 1997;154:516-522.
-
(1997)
Am J Psychiatry
, vol.154
, pp. 516-522
-
-
Strauss, W.L.1
Layton, M.E.2
Hayes, C.E.3
-
30
-
-
0020536393
-
Review of the animal pharmacology and pharmacokinetics of fluvoxamine
-
Claassen V. 1983. Review of the animal pharmacology and pharmacokinetics of fluvoxamine. Br J Clin Pharmacol. 15 Suppl 3:349S-355S.
-
(1983)
Br J Clin Pharmacol
, vol.15
, Issue.SUPPL. 3
-
-
Claassen, V.1
-
31
-
-
0031941954
-
Brain elimination half-life of fluvoxamine measured by 19F magnetic resonance spectroscopy
-
Strauss WL, Layton ME, Dager SR. Brain elimination half-life of fluvoxamine measured by 19F magnetic resonance spectroscopy. Am J Psychiatry. 1998;155:380-384.
-
(1998)
Am J Psychiatry
, vol.155
, pp. 380-384
-
-
Strauss, W.L.1
Layton, M.E.2
Dager, S.R.3
-
33
-
-
48549093980
-
Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update
-
Spina E, Santoro V, D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther. 2008;30:1206-1227.
-
(2008)
Clin Ther
, vol.30
, pp. 1206-1227
-
-
Spina, E.1
Santoro, V.2
D'Arrigo, C.3
-
34
-
-
34249911648
-
Fluvoxamine in the treatment of anxiety disorders
-
Irons J. Fluvoxamine in the treatment of anxiety disorders. Neuropsychiatr Dis Treat. 2005;1:289-299.
-
(2005)
Neuropsychiatr Dis Treat
, vol.1
, pp. 289-299
-
-
Irons, J.1
-
35
-
-
0023472494
-
Fluvoxamine treatment of obsessive-compulsive disorder
-
Perse TL, Greist JH, Jefferson JW, et al. Fluvoxamine treatment of obsessive-compulsive disorder. Am J Psychiatry. 1987;144:1543-1548.
-
(1987)
Am J Psychiatry
, vol.144
, pp. 1543-1548
-
-
Perse, T.L.1
Greist, J.H.2
Jefferson, J.W.3
-
36
-
-
0024986443
-
A controlled trial of fluvoxamine in obsessive-compulsive disorder: Implications for a serotonergic theory
-
Jenike MA, Hyman S, Baer L, et al. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. Am J Psychiatry. 1990;147:1209-1215. (Pubitemid 20275377)
-
(1990)
American Journal of Psychiatry
, vol.147
, Issue.9
, pp. 1209-1215
-
-
Jenike, M.A.1
Hyman, S.2
Baer, L.3
Holland, A.4
Minichiello, W.E.5
Buttolph, L.6
Summergrad, P.7
Seymour, R.8
Ricciardi, J.9
-
37
-
-
0000964732
-
Efficacy of fluvoxamine in obsessive-compulsive disorder: Results of a multicentre, double-blind, placebo-controlled trial
-
Greist JH, Jenike MA, Robinson D, et al. Efficacy of fluvoxamine in obsessive-compulsive disorder: results of a multicentre, double-blind, placebo-controlled trial. Eur J Clin Res. 1995;7:195-204.
-
(1995)
Eur J Clin Res
, vol.7
, pp. 195-204
-
-
Greist, J.H.1
Jenike, M.A.2
Robinson, D.3
-
38
-
-
0029925952
-
Treatment of obsessive-compulsive disorder with fluvoxamine: A multicentre, double-blind, placebo-controlled trial
-
Goodman WK, Kozak MJ, Liebowitz M, et al. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int Clin Psychopharmacol. 1996;11:21-29. (Pubitemid 26133288)
-
(1996)
International Clinical Psychopharmacology
, vol.11
, Issue.1
, pp. 21-29
-
-
Goodman, W.K.1
Kozak, M.J.2
Liebowitz, M.3
White, K.L.4
-
39
-
-
0027527041
-
Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: One-year followup
-
DOI 10.1016/0165-1781(93)90030-K
-
Cottraux J, Mollard E, Bouvard M, et al. Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: one-year followup. Psychiatry Res. 1993;49:63-75. (Pubitemid 23329247)
-
(1993)
Psychiatry Research
, vol.49
, Issue.1
, pp. 63-75
-
-
Cottraux, J.1
Mollard, E.2
Bouvard, M.3
Marks, I.4
-
40
-
-
7344243785
-
Combination of behaviour therapy with fluvoxamine in comparison with behaviour. Results of a multicentre study
-
Hohagen F, Winkelmann G, Rasche-Rüchle H, et al. Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study. Br J Psychiatry. 1998;35 Suppl:71-78. (Pubitemid 28368353)
-
(1998)
British Journal of Psychiatry
, vol.173
, Issue.SUPPL. 35
, pp. 71-78
-
-
Hohagen, F.1
Winkelmann, G.2
Rasche-Rauchle, H.3
Hand, I.4
Konig, A.5
Munchau, N.6
Hiss, H.7
Geiger-Kabisch, C.8
Kappler, C.9
Schramm, P.10
Rey, E.11
Aldenhoff, J.12
Berger, M.13
-
41
-
-
0028059773
-
Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: A multicenter, randomized, double-blind, parallel group comparison
-
Freeman CP, Trimble MR, Deakin JF, et al. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. J Clin Psychiatry. 1994;55:301-305.
-
(1994)
J Clin Psychiatry
, vol.55
, pp. 301-305
-
-
Freeman, C.P.1
Trimble, M.R.2
Deakin, J.F.3
-
42
-
-
0029947585
-
Fluvoxamine versus clomipramine for obsessive-compulsive disorder: A double-blind comparison
-
DOI 10.1097/00004714-199604000-00004
-
Koran LM, McElroy SL, Davidson JR, et al. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. J Clin Psychopharmacol. 1996;16:121-129. (Pubitemid 26142900)
-
(1996)
Journal of Clinical Psychopharmacology
, vol.16
, Issue.2
, pp. 121-129
-
-
Koran, L.M.1
Mcelroy, S.L.2
Davidson, J.R.T.3
Rasmussen, S.A.4
Hollander, E.5
Jenike, M.A.6
-
43
-
-
0030848079
-
A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder
-
Milanfranchi A, Ravagli S, Lensi P, et al. A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 1997;12:131-136. (Pubitemid 27283320)
-
(1997)
International Clinical Psychopharmacology
, vol.12
, Issue.3
, pp. 131-136
-
-
Milanfranchi, A.1
Ravagli, S.2
Lensi, P.3
Marazziti, D.4
Cassano, G.B.5
-
44
-
-
0034010178
-
Multicentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder
-
Mundo E, Maina G, Uslenghi C. Multicentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 2000;15:69-76. (Pubitemid 30142798)
-
(2000)
International Clinical Psychopharmacology
, vol.15
, Issue.2
, pp. 69-76
-
-
Mundo, E.1
Maina, G.2
Uslenghi, C.3
-
45
-
-
0034833763
-
Fluvoxamine in obsessive-compulsive disorder: Similar efficacy but superior tolerability in comparison with clomipramine
-
DOI 10.1002/hup.317
-
Mundo E, Rouillon F, Figuera ML, et al. Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine. Hum Psychopharmacol. 2001;16:461-468. (Pubitemid 32895589)
-
(2001)
Human Psychopharmacology
, vol.16
, Issue.6
, pp. 461-468
-
-
Mundo, E.1
Rouillon, F.2
Luisa Figuera, M.3
Stigler, M.4
-
46
-
-
0028905968
-
Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder
-
Stein DJ, Spadaccini E, Hollander E. Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int Clin Psychopharmacol. 1995;10:11-18.
-
(1995)
Int Clin Psychopharmacol
, vol.10
, pp. 11-18
-
-
Stein, D.J.1
Spadaccini, E.2
Hollander, E.3
-
47
-
-
0029889666
-
Drug treatment of obsessive-compulsive disorder (OCD): Long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs)
-
Ravizza L, Barzega G, Bellino S, et al. Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRI). Psychopharmacol Bull. 1996;32:167-173. (Pubitemid 26176218)
-
(1996)
Psychopharmacology Bulletin
, vol.32
, Issue.1
, pp. 167-173
-
-
Ravizza, L.1
Barzega, G.2
Bellino, S.3
Bogetto, F.4
Maina, G.5
-
48
-
-
0031014507
-
Long-term pharmacotherapy of obsessive-compulsive disorder: A double-blind controlled study
-
DOI 10.1097/00004714-199702000-00002
-
Mundo E, Bareggi SR, Pirola R, et al. Long-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled study. J Clin Psychopharmacol. 1997;17:4-10. (Pubitemid 27047255)
-
(1997)
Journal of Clinical Psychopharmacology
, vol.17
, Issue.1
, pp. 4-10
-
-
Mundo, E.1
Bareggi, S.R.2
Pirola, R.3
Bellodi, L.4
Smeraldi, E.5
-
49
-
-
0036850509
-
Predictors of fluvoxamine response in contamination-related obsessive compulsive disorder: A PET symptom provocation study
-
Rauch SL, Shin LM, Dougherty DD, et al. Predictors of fluvoxamine response in contamination-related obsessive compulsive disorder: a PET symptom provocation study. Neuropsychopharmacology. 2002;27:782-791.
-
(2002)
Neuropsychopharmacology
, vol.27
, pp. 782-791
-
-
Rauch, S.L.1
Shin, L.M.2
Dougherty, D.D.3
-
50
-
-
17644409732
-
Decreased thalamic blood flow in obsessive-compulsive disorder patients responding to fluvoxamine
-
Ho Pian KL, van Megen HJ, Ramsey NF, et al. Decreased thalamic blood flow in obsessive-compulsive disorder patients responding to fluvoxamine. Psychiatry Res. 2005;138:89-97.
-
(2005)
Psychiatry Res
, vol.138
, pp. 89-97
-
-
Ho Pian, K.L.1
Van Megen, H.J.2
Ramsey, N.F.3
-
51
-
-
0032973086
-
Cognitive-behaviour therapy and medication in the treatment of obsessive-compulsive disorder: A controlled study
-
O'Connor K, Todorov C, Robillard S, et al. Cognitive-behaviour therapy and medication in the treatment of obsessive-compulsive disorder: a controlled study. Can J Psychiatry. 1999;44:64-71. (Pubitemid 29146429)
-
(1999)
Canadian Journal of Psychiatry
, vol.44
, Issue.1
, pp. 64-71
-
-
O'Connor, K.1
Todorov, C.2
Robillard, S.3
Borgeat, F.4
Brault, M.5
-
52
-
-
17644419272
-
Clinical outcome in patients with obsessive-compulsive disorder after discontinuation of SRI treatment: Results from a two-year follow-up
-
DOI 10.1007/s00406-004-0533-y
-
Kordon A, Kahl KG, Broocks A, et al. Clinical outcome in patients with obsessive-compulsive disorder after discontinuation of SRI treatment: results from a two-year follow-up. Eur Arch Psychiatry Clin Neurosci. 2005;255:48-50. (Pubitemid 40558105)
-
(2005)
European Archives of Psychiatry and Clinical Neuroscience
, vol.255
, Issue.1
, pp. 48-50
-
-
Kordon, A.1
Kahl, K.G.2
Broocks, A.3
Voderholzer, U.4
Rasche-Rauchle, H.5
Hohagen, F.6
-
53
-
-
0037929415
-
A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder
-
Hollander E, Koran LM, Goodman WK, et al. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry. 2003;64:640-647. (Pubitemid 36750140)
-
(2003)
Journal of Clinical Psychiatry
, vol.64
, Issue.6
, pp. 640-647
-
-
Hollander, E.1
Koran, L.M.2
Goodman, W.K.3
Greist, J.H.4
Ninan, P.T.5
Yang, H.6
Li, D.7
Barbato, L.M.8
-
54
-
-
0036234093
-
Sertraline treatment of obsessive-compulsive disorder: Efficacy and tolerability of a rapid titration regimen
-
Bogetto F, Albert U, Maina G. Sertraline treatment of obsessive-compulsive disorder: efficacy and tolerability of a rapid titration regimen. Eur Neuropsychopharmacol. 12:181-186.
-
Eur Neuropsychopharmacol
, vol.12
, pp. 181-186
-
-
Bogetto, F.1
Albert, U.2
Maina, G.3
-
55
-
-
1542650167
-
Immediate-release versus controlled-release formulations: Pharmacokinetics of newer antidepressants in relation to nausea
-
DeVane CL. Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea. J Clin Psychiatry. 2003;64 Suppl 18:14-19.
-
(2003)
J Clin Psychiatry
, vol.64
, Issue.SUPPL. 18
, pp. 14-19
-
-
Devane, C.L.1
-
56
-
-
0028359427
-
A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder
-
Tollefson GD, Rampey AH Jr, Potvin JH, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry. 1994;51:559-567.
-
(1994)
Arch Gen Psychiatry
, vol.51
, pp. 559-567
-
-
Tollefson, G.D.1
Rampey Jr., A.H.2
Potvin, J.H.3
-
57
-
-
0029759206
-
Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder
-
OCD Paroxetine Study Investigators
-
Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators. Br J Psychiatry. 1996;169:468-474.
-
(1996)
Br J Psychiatry
, vol.169
, pp. 468-474
-
-
Zohar, J.1
Judge, R.2
-
58
-
-
0028911928
-
Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder
-
Greist J, Chouinard G, DuBoff E, et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1995;52: 289-295.
-
(1995)
Arch Gen Psychiatry
, vol.52
, pp. 289-295
-
-
Greist, J.1
Chouinard, G.2
Duboff, E.3
-
59
-
-
0031918221
-
Pulse loading versus gradual dosing of intravenous clomipramine in obsessive-compulsive disorder
-
DOI 10.1016/S0924-977X(97)00048-5, PII S0924977X97000485
-
Koran LM, Pallanti S, Paiva RS, et al. Pulse loading versus gradual dosing of intravenous clomipramine in obsessive-compulsive disorder. Eur Neuropsychopharmacol. 1998;8:121-126. (Pubitemid 28210338)
-
(1998)
European Neuropsychopharmacology
, vol.8
, Issue.2
, pp. 121-126
-
-
Koran, L.M.1
Pallanti, S.2
Paiva, R.S.3
Quercioli, L.4
-
60
-
-
1642539050
-
A Double-Blind Placebo-Controlled Study of Controlled Release Fluvoxamine for the Treatment of Generalized Social Anxiety Disorder
-
DOI 10.1097/01.jcp.0000104906.75206.8b
-
Westenberg HG, Stein DJ, Yang H, et al. A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol. 2004;24:49-55. (Pubitemid 38134166)
-
(2004)
Journal of Clinical Psychopharmacology
, vol.24
, Issue.1
, pp. 49-55
-
-
Westenberg, H.G.M.1
Stein, D.J.2
Yang, H.3
Li, D.4
Barbato, L.M.5
-
61
-
-
18144368022
-
-
Luvox. Palo Alto: Jazz Pharmaceuticals, Inc.
-
Luvox. 2004. Prescribing Information. Palo Alto: Jazz Pharmaceuticals, Inc.
-
(2004)
Prescribing Information
-
-
-
62
-
-
1642307074
-
Fluvoxamine-Controlled Release Formulation for the Treatment of Generalized Social Anxiety Disorder
-
DOI 10.1097/01.jcp.0000106222.36344.96
-
Davidson J, Yaryura-Tobias J, DuPont R, et al. Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol. 2004;24:118-125. (Pubitemid 38380834)
-
(2004)
Journal of Clinical Psychopharmacology
, vol.24
, Issue.2
, pp. 118-125
-
-
Davidson, J.1
Yaryura-Tobias, J.2
Dupont, R.3
Stallings, L.4
Barbato, L.M.5
Van Der Hoop, R.G.6
Li, D.7
|